Significant Rise in ME/CFS Cases at Austrian Pension Authority, Yet Few Approvals

The Austrian Pension Insurance Agency (PVA) has recorded a dramatic increase in cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) since 2019. In that year, the PVA identified ME/CFS as the primary diagnosis in only 16 applications for disability and invalidity pensions or rehabilitation benefits. By 2024, this figure had surged to 288, representing an increase of approximately 1,700 percent. These statistics do not account for applicants who presented with an ME/CFS diagnosis that was not recognized or adopted by the PVA.

Accompanying this rise in case numbers, the rejection rate for ME/CFS-related benefit applications has also grown substantially. Data provided in response to a parliamentary inquiry revealed that the rejection rate climbed from 57 percent in 2022 to 66 percent in 2024. In earlier years, when ME/CFS was diagnosed less frequently by the PVA, rejection rates ranged between 27 and 50 percent. The total number of applications from individuals affected by ME/CFS remains unclear, as the PVA does not record the initial diagnoses provided by applicants, but only those assigned by its medical reviewers.

Regarding the assessment process, the PVA has stated that its medical assessors operate independently within the framework of professional legal regulations. These assessors may utilize any guidelines recognized and validated by relevant medical societies. The PVA itself does not issue specific medical instructions for ME/CFS assessments nor does it provide specialized training for its reviewers in dealing with ME/CFS cases. Training obligations and oversight are handled by professional medical bodies, such as the Austrian Medical Chamber, rather than the PVA.

Questions have been raised about the adequacy of expertise among medical reviewers tasked with evaluating ME/CFS applications. Critics highlight the lack of systematic oversight to ensure assessors are qualified to make such determinations. Furthermore, the PVA does not track the initial diagnoses applicants submit, making it difficult to evaluate the full scope of ME/CFS cases it handles.

Independent research has highlighted challenges faced by ME/CFS and Post-COVID patients in securing benefit approvals. A joint investigation by Austrian news outlets indicated that 79 percent of such applications were denied or previously granted benefits were revoked. In more than half of reviewed cases, the ME/CFS or Post-COVID diagnosis was entirely dismissed by reviewers, and in about 40 percent, it was reclassified as a psychological or psychosomatic condition. Applicants were sometimes reported to have exaggerated or simulated symptoms, complicating their claims further.

Concerns have also been raised about the impact of misdiagnoses, particularly when rehabilitation benefits are approved under incorrect diagnoses. According to advocacy groups, this can result in inappropriate rehabilitation plans and, in some cases, the requirement for applicants to undergo psychiatric treatment. There have also been questions about the quality of medical assessments, with some reports suggesting that poorly conducted evaluations result in unsuitable treatment recommendations that applicants are nevertheless obliged to follow.

Legal recourse is available for applicants wishing to appeal PVA decisions, and these proceedings are free of charge. However, data indicates that such appeals are rarely successful. Between 2022 and 2025, only 9 percent of the 411 appeals lodged by applicants with an ME/CFS diagnosis resulted in a favorable outcome. The PVA has not provided information regarding the costs associated with obtaining medical opinions or the number of expert assessments conducted annually.

In response to recent discussions about derogatory remarks allegedly made by PVA officials regarding ME/CFS patients and their doctors, the Social Affairs Ministry has emphasized its commitment to improving the situation for those affected and developing better medical care pathways. However, critics argue that the lack of direct engagement with PVA leadership and the reliance on institutional self-governance may hinder progress in addressing the challenges faced by ME/CFS sufferers within the pension system.